BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy., Cerchietti, Leandro C., Hatzi Katerina, Caldas-Lopes Eloisi, Yang Shao Ning, Figueroa Maria E., Morin Ryan D., Hirst Martin, Mendez Lourdes, Shaknovich Rita, Cole Philip A., et al. , J Clin Invest, 2010 Dec 01, Volume 120, Issue 12, p.4569-82, (2010)

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas., Cerchietti, Leandro, Damm-Welk Christine, Vater Inga, Klapper Wolfram, Harder Lana, Pott Christiane, Yang Shao Ning, Reiter Alfred, Siebert Reiner, Melnick Ari, et al. , PLoS One, 2011 Apr 08, Volume 6, Issue 4, p.e18436, (2011)

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo., Fontan, Lorena, Yang Chenghua, Kabaleeswaran Venkataraman, Volpon Laurent, Osborne Michael J., Beltran Elena, Garcia Monica, Cerchietti Leandro, Shaknovich Rita, Yang Shao Ning, et al. , Cancer Cell, 2012 Dec 11, Volume 22, Issue 6, p.812-24, (2012)

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo., Cerchietti, Leandro C., Yang Shao Ning, Shaknovich Rita, Hatzi Katerina, Polo Jose M., Chadburn Amy, Dowdy Steven F., and Melnick Ari , Blood, 2009 Apr 09, Volume 113, Issue 15, p.3397-405, (2009)

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma., Goldstein, Rebecca L., Yang Shao Ning, Taldone Tony, Chang Betty, Gerecitano John, Elenitoba-Johnson Kojo, Shaknovich Rita, Tam Wayne, Leonard John P., Chiosis Gabriela, et al. , J Clin Invest, 2015 Nov 03, Volume 125, Issue 12, p.4559-71, (2015)